Literature DB >> 25108807

Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.

Qiaoqiao Li1, Cameron W Swanick1, Pamela K Allen1, Daniel R Gomez1, James W Welsh1, Zhongxing Liao1, Peter A Balter1, Joe Y Chang2.   

Abstract

BACKGROUND AND
PURPOSE: We report our outcomes for patients with NSCLC treated with SABR to 70 Gy in 10 fractions and propose indications for this regimen as well as new dose-volume constraints.
MATERIALS AND METHODS: Volumetric image-guided SABR was used to treat 82 patients with clinical challenging NSCLC, not suitable for 50 Gy in 4 fractions, to a final dose of 70 Gy in 10 fractions. Endpoints included overall survival (OS), toxicity, and disease control.
RESULTS: At a median follow-up time of 21.1 months, 2-year OS and local control rates were 66.9% and 96.2%, respectively. The most common side effects were radiation pneumonitis (14.6% grade 2, 2.4% grade 3), followed by chest wall pain (4.9% grade 2, 1.2% grade 3). Multivariate analysis revealed chest wall V50>60 cm(3) to be associated with chest wall pain. No patient developed brachial plexopathy. One patient with bronchial tree tumor invasion died of hemoptysis.
CONCLUSIONS: SABR with 70 Gy in 10 fractions appears to achieve excellent local control and acceptable toxicity for clinically challenging cases with improved tolerance of the chest wall and brachial plexus as compared with 50 Gy in 4 fractions. This regimen may not be suitable in patients with tumor invading critical central structures. More studies are needed to validate our conclusions.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Central lesion; Hypofractionation; NSCLC; SABR; SBRT

Mesh:

Year:  2014        PMID: 25108807     DOI: 10.1016/j.radonc.2014.07.010

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

1.  Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Authors:  Ursula Nestle; José Belderbos
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

3.  Stereotactic ablative radiotherapy: aim for a cure of cancer.

Authors:  Joe Y Chang
Journal:  Ann Transl Med       Date:  2015-01

4.  Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.

Authors:  Lauren Henke; Rojano Kashani; Deshan Yang; Tianyu Zhao; Olga Green; Lindsey Olsen; Vivian Rodriguez; H Omar Wooten; H Harold Li; Yanle Hu; Jeffrey Bradley; Clifford Robinson; Parag Parikh; Jeff Michalski; Sasa Mutic; Jeffrey R Olsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-08-31       Impact factor: 7.038

5.  Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.

Authors:  Eric D Brooks; Bing Sun; Lina Zhao; Ritsuko Komaki; Zhonxing Liao; Melenda Jeter; James W Welsh; Michael S O'Reilly; Daniel R Gomez; Stephen M Hahn; John V Heymach; David C Rice; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-21       Impact factor: 7.038

6.  Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach : A prospective observational study.

Authors:  Rosario Mazzola; Ruggero Ruggieri; Vanessa Figlia; Michele Rigo; Niccolò Giaj Levra; Francesco Ricchetti; Luca Nicosia; Stefanie Corradini; Filippo Alongi
Journal:  Strahlenther Onkol       Date:  2019-01-28       Impact factor: 3.621

7.  Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.

Authors:  Vanessa Figlia; Rosario Mazzola; Francesco Cuccia; Filippo Alongi; Gianluca Mortellaro; Daniela Cespuglio; Teresa Cucchiara; Giuseppina Iacoviello; Vito Valenti; Massimo Molino; Francesco Verderame; Domenica Matranga; Antonio Lo Casto; Giuseppe Ferrera
Journal:  Radiol Med       Date:  2018-02-17       Impact factor: 3.469

8.  Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.

Authors:  Louise Murray; Ebru Karakaya; Samantha Hinsley; Mitchell Naisbitt; John Lilley; Michael Snee; Katy Clarke; Hima B Musunuru; Satiavani Ramasamy; Rob Turner; Kevin Franks
Journal:  Br J Radiol       Date:  2016       Impact factor: 3.039

Review 9.  Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances.

Authors:  Nikhil T Sebastian; Meng Xu-Welliver; Terence M Williams
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 10.  Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research.

Authors:  Eugenia Vlaskou Badra; Michael Baumgartl; Silvia Fabiano; Aurélien Jongen; Matthias Guckenberger
Journal:  Transl Lung Cancer Res       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.